BBIO vs LNTH
BridgeBio Pharma, Inc. vs Lantheus Holdings — AI-powered side-by-side comparison
BBIO
BridgeBio Pharma, Inc.
65
Insufficient Data
VS
LNTH
Lantheus Holdings
67
Buy
| Metric | BBIO | LNTH |
|---|
| AI Score |
65
|
67
|
| Price |
$83.71
|
$100.63
|
| P/E Ratio |
-23.38×
|
23.91×
|
| ROE |
35.1%
|
21.4%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
93.1%
|
60.1%
|
| Debt / Equity |
-0.99×
|
0.44×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
56.9
|
42.5
|
| Beta |
0.983
|
-0.057
|
| Expected Upside |
—
|
+7.8%
|
AI Committee View
Current Innellis committee reasoning for BBIO versus LNTH.
LNTH leads by 2 points.
LNTH scores 67/100 (Buy) versus BBIO at 65/100 (Insufficient Data).
BBIO Committee View
67% agreement
3 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
LNTH Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- 3 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical